2023-06-27 10:00:23
On the Sanofi site in Vitry-sur-Seine (Val-de-Marne), September 9, 2022. THOMAS SAMSON / AFP
It was just two years ago. In front of industrialists and health professionals gathered at the Elysée, on the occasion of the Strategic Council for Health Industries, Emmanuel Macron unveiled his roadmap for “to make France the leading innovative nation in health in Europe by 2030”. Under the watchful eye of pharmaceutical laboratories, the Head of State promised measures to restore the competitiveness and attractiveness of France. Welcoming commitments “up to the challenge”the professional organization of drug manufacturers, the LEEM, had left the presidential residence reassured by the announcements.
Read also the interview: Article reserved for our Medicines subscribers: “France has lost considerably its attractiveness in terms of innovation”
Since then, the Social Security financing bill for 2023, presented in the fall of 2022 and voted on in December, has shattered the expectations of laboratories. Denouncing the logic “purely accounting” of the state, which “turns its back on innovation” et « sounds the death knell for France’s industrial ambitions », LEEM had immediately launched a vast project to detail the consequences. On Tuesday 27 June, the professional organization presented the conclusions of this “seismograph intended to measure the magnitude of the tremor”. “The results of this first edition place France as a very average student in Europe”summarizes the organization.
In detail, this Observatory of access to medicines and attractiveness in France, which is intended to be updated every six months, draws up a less than rosy observation of France’s position vis-à-vis of its European neighbours.
Access to new treatments
First, on patient access to new treatments. At the end of 2022, 34% of the drugs having received marketing authorization from the European Medicines Agency, between 2018 and 2021, were still not available for French patients, notes the study.
Read also: Article reserved for our subscribers Shortages of medicines: from Ardèche, Emmanuel Macron announces an acceleration of relocation
If Spain and England show comparable results, this proportion remains very far from the figures aligned by the good students in the ranking, Germany (13%) and Italy (19%). These disparities are explained by the extent of the administrative delays observed in France. Because once the European green light has been won, a drug must validate several stages with the local regulatory authorities to be marketed.
However, if the High Authority for Health (HAS) has made efforts to reduce its procedural times – the median time for evaluating files has decreased by twenty-two days between 2019 and 2022 –, at the same time, that of price and publication negotiations Official newspaper lengthened by ninety-six days, underlines the LEEM.
You have 45.88% of this article left to read. The following is for subscribers only.
1687897579
#pharmaceutical #companies #concerned #loss #attractiveness #France
